Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing

Open access
Farrell, Barbara, Pottie, Kevin, Rojas-Fernandez, Carlos H., Bjerre, Lise M., Thompson, Wade, Welch, Vivian · 2016 · PLOS ONE

Abstract

BACKGROUND: Class specific deprescribing guidelines could help clinicians taper and stop medications no longer needed or which may be causing more harm than benefit. We set out to develop methodology to create such guidelines using evidence-based methods for guideline development, evidence synthesis and recommendation rating. METHODS AND FINDINGS: Using a comprehensive checklist for a successful guideline enterprise, we conducted a national modified Delphi consensus process to identify priorities for deprescribing guidelines, then conducted scoping exercises to identify feasible topics, and sequentially developed three deprescribing guidelines. We selected guideline development team members for clinical expertise; a GRADE member worked with staff to ensure guideline development processes were followed. We conducted or used systematic searches and reviews of deprescribing trials of selected drug classes, reviews or systematic reviews of drug class effectiveness, reviews of reviews of drug class harm and narrative syntheses of contextual questions to inform recommendations and guideline development. Our 8 step process for guideline development included defining scope and purpose, developing a logic model to guide the process and generate key clinical questions, setting criteria for admissible evidence and conducting systematic reviews, synthesizing evidence considering additional contextual information and performing quality estimates, formulating recommendations and providing strength estimations, adding clinical considerations, conducting clinical and stakeholder review and finally updating content pre-publication. Innovative aspects of the guideline development process included synthesizing evidence for outcomes of tapering or stopping medication, and incorporating evidence for medication harm into the recommendation strength rating. Through the development of three deprescribing guidelines (for proton pump inhibitors, benzodiazepine receptor agonists and antipsychotics) and associated decision-support algorithms, we were able to gradually hone the methodology; each guideline will be published separately. CONCLUSION: Our methodology demonstrates the importance of searching for short and long-term outcomes, showing the benefits of deprescribing and studying patient preferences. This publication will support development of future deprescribing guidelines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0161248

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Overall methodology for deprescribing guideline preparation, development, implementation and revision.
Fig 1 Overall methodology for deprescribing guideline preparation, development, implementation and revision.CC BY · PubMed Central
Fig 2 Steps used to develop deprescribing guidelines.
Fig 2 Steps used to develop deprescribing guidelines.CC BY · PubMed Central
Fig 3 Generic Deprescribing Logic Model.
Fig 3 Generic Deprescribing Logic Model.CC BY · PubMed Central
Fig 4 Sample clinical consideration questions.
Fig 4 Sample clinical consideration questions.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 134

Metadata

Authors
Farrell, B., Pottie, K., Rojas-Fernandez, C. H., Bjerre, L. M., Thompson, W., & Welch, V.
Affiliations
  • University of Waterloo (CA)
  • University of Ottawa (CA)
Corresponding author
Farrell, Barbara
Venue
PLOS ONE
Published
2016-08-12
Volume
11
Issue
8
Pages
e0161248
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2510306467
Cited by
134
References
42
Citations by year
2026: 9 · 2025: 6 · 2024: 10 · 2023: 25 · 2022: 17 · 2021: 7 · 2020: 21 · 2019: 13 · 2018: 18 · 2017: 8
FWCI
7.49
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • uO Research (University of Ottawa) (submittedVersion, public-domain)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • University of Ottawa - Library
Funders
Government of Ontario (#06674)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
  • Health Sciences › Health Professions › General Health Professions › Healthcare cost, quality, practices
Keywords
deprescribing, guideline development methodology, GRADE, strength of recommendation, medication tapering, drug-related harm, proton pump inhibitors, benzodiazepine receptor agonists, antipsychotic drugs, decision support algorithm, Delphi consensus, evidence synthesis, patient preferences
MeSH terms
Deprescriptions, Health Services Needs and Demand, Humans, Drug Prescriptions, Practice Guidelines as Topic, Evidence-Based Medicine, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. https://app.cochat.ai/papers/10.1371/journal.pone.0161248
The paper
Farrell, B., Pottie, K., Rojas-Fernandez, C. H., Bjerre, L. M., Thompson, W., & Welch, V. (2016). Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. PLOS ONE. https://doi.org/10.1371/journal.pone.0161248

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.